Keywords: Janssen, Johnson & Johnson, Bedaquiline, Sirturo, Tuberculosis, MDR-TB, USA, FDA advisory

FDA panel backs accelerated approval of Janssen's bedaquiline for MDR-TB

Article | 29 November 2012

Janssen Research & Development, a unit of US health care major Johnson & Johnson (NYSE: JNJ), says that, in a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in